H.C. Wainwright raises Verastem stock price target to $20 on drug progress
H.C. Wainwright raised its price target on Verastem Inc. (VSTM) to $20 from $18, citing progress in its VS-7375 drug candidate. The stock trades at $9.38, with a consensus Buy rating. Verastem reported Q3 revenue of $24.01M, missing estimates but up 114% YoY. The company's gross profit margin is 87.6%.
How this was made
The 30-second read
Why it matters
The analyst’s target raise reflects confidence in the pipeline, potentially outweighing the earnings miss in the short term.
Market read
New analyst target could trigger buying pressure in VSTM, with limited broader market impact.
What to watch
Execution risk on upcoming trial data and the modest size of the price‑target increase may temper price gains.
Background
Verastem reported a Q3 loss and revenue below estimates, but its pancreatic cancer candidate VS‑7375 is moving toward pivotal trials.
Ticker impact
H.C. Wainwright raised its price target on Verastem Inc. (VSTM) to $20 from $18 and maintained a Buy rating.
upward pressure as investors price in the higher target
The new $20 target is a fresh analyst action that can prompt buying interest; no countervailing news was presented.
Market effects
Positive sentiment may spill over to other biotech firms developing KRAS‑targeted therapies.
Limited to U.S. biotech sector.
Minor, confined to investors tracking small‑cap oncology stocks.
Counterpoint
The recent Q3 earnings miss and revenue shortfall could limit upside despite the higher target.
Key entities
- companyVerastem Inc.
Biotech company developing KRAS‑mutant cancer therapies.
- analyst_firmH.C. Wainwright
Equity research firm that raised the price target.


